Evotec Says DiaPep Demise Delays Goals, Spotlight Now On Roche Pact
This article was originally published in The Pink Sheet Daily
With the disappearance of DiaPep277 due to presumed fraud, Evotec is now looking to its partnership with Roche in Alzheimer’s to bring the German biotech’s first drug to market - but the timeframe will be longer.
You may also be interested in...
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
In a novel move to overcome the slowdown in outsourcing, small-molecule drug discovery company Evotec has bought asset manager Bionamics to more quickly progress assets originating in German academia.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.